Inhibitory effect of ebselen on cerebral acetylcholinesterase activity in vitro: Kinetics and reversibility of inhibition

Current Pharmaceutical Design

Volumn 21, Issue 7, 2015, Pages 920-924

  Martini, Franciele ^a   Brüning, César Augusto ^a   Soares, Suelen Mendonça ^a   Nogueira, Cristina Wayne ^a   Zeni, Gilson ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Acetylcholinesterase; Brain; Ebselen; Kinetics profile; Mixed; Rat; Reversibility; Selenium

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE; EBSELEN; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOSELENIUM DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSIS; DRUG EFFECT; ELECTROPHORUS; ENZYME ACTIVITY; ENZYME INHIBITION; IC50; IN VITRO STUDY; INHIBITION KINETICS; MALE; MAXIMUM REACTION VELOCITY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; ANIMAL; BLOOD BRAIN BARRIER; BRAIN CORTEX; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; AZOLES; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; ENZYME ACTIVATION; MALE; ORGANOSELENIUM COMPOUNDS; RATS; RATS, WISTAR;

EID: 84925879721     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141014124319     Document Type: Article

References (48)

1. Dereu NH, Fischer G, Hilboll A, Roemer R Terlinden. The use of highly enriched Se in metabolic studies of ebselen in man. An NMR investigation, in: A. Wendel (Ed.), Selenium in Biology and Medicine, Springer-Verlag, Heidelberg, Germany 1989; pp: 163-8.
2. [2] Nogueira CW, Zeni G, Rocha JBT. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev 2004; 104: 6255-86.
3. [3] Yamagata K, Ichinose S, Miyashita A, Tagami M. Protective effects of ebselen, a seleno-organic antioxidant on neurodegeneration induced by hypoxia and reperfusion in stroke-prone spontaneously hypertensive rat. Neuroscience 2008; 153: 428-35.
4. [4] Gabryel B, Małecki A. Ebselen attenuates oxidative stress in ischemic astrocytes depleted of glutathione. Comparison with glutathione precursors. Pharmacol Rep 2006; 58: 381-92.
5. [5] Pérez-Ortiz JM, Tranque P, Vaquero CF, et al. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferatoractivated receptor-gamma. J Biol Chem 2004; 279: 8976-85.
6. [6] Schewe T. Molecular actions of ebselen an anti-inflammatory antioxidant. Gen Pharmacol 1995; 26: 1153-69.
7. [7] Ogawa A, Yoshimoto T, Kikuchi H, et al. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 1999; 9: 112-18.
8. Stroke Trials Registry [homepage on the Internet]. Available online: http://www.strokecenter.org/trials/(accessed on 27 January 2014).
9. [9] ClinicalTrials.gov.A service of the U.S. National Institutes of Health [homepage on the Internet]. Available online: http: //clinicaltrials.gov/ct2/home (accessed on 27 January 2014).
10. [10] Luo Z, Sheng J, Sun Y, et al. Synthesis and Evaluation of Multi- Target-Directed Ligands against Alzheimer’s Disease Based on the Fusion of Donepezil and Ebselen. J Med Chem 2013; 56(22): 9089-99.
11. [11] Luo Z, Liang L, Sheng J, et al.. Synthesis and biological evaluation of a new series of Ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease. Bioorg Med Chem 2014; http://dx.doi.org/10.1016/j.bmc.2013.12.066
12. [12] Mazzanti CM, Spanevello RM, Obregon A, et al. Ethidium bromide inhibits rat brain acetylcholinesterase activity in vitro. Chem Biol Interact 2006; 162: 121-7.
13. [13] Costa MD, Gai BM, Acker CI et al. Ebselen reduces hyperglycemia temporarily-induced by diazinon: A compound with insulinmimetic properties. Chem Biol Interact 2012; 197: 80-6.
14. [14] Soreq H, Seidman S. Acetylcholinesterase-new roles for and old actor. Nat Rev Neurosci 2001; 2: 294-302.
15. [15] Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 2002; 110: 627-39.
16. [16] Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptons in alzheimer disease. Am J Geriatr Psychiatry 1998; 6: 64-78.
17. [17] Schliebs R, Arendt T. The significance of the cholinergic system in the brainduring aging and in Alzheimer’s disease. J Neural Transm1 2006; 13: 1625-44.
18. [18] Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol 2006; 245: 177-81.
19. [19] Engman L, Hallberg A. Expedient Synthesis of Ebselen and Related Compounds. J Org Chem1989; 54: 2964-66.
20. [20] Ellman GL, Courtney KD, Andres V Jr, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
21. [21] Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976; 72: 248-54.
22. [22] Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174: 788-95.
23. [23] Drachman DA, Leavitt J. Human memory and the central cholinergic system: a relationship to aging. Arch Neurol 1974; 30: 113-21.
24. [24] Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-44.
25. [25] Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-15.
26. [26] McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 1999; 48: 471-80.
27. [27] Tabet N. Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing! Age Ageing 2006; 35: 336-38.
28. [28] Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-38.
29. [29] Forette F, Anand R, Gharabawi G.A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (ExXelon). Eur J Neurol 1999; 6: 423-29.
30. [30] Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-_-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91.
31. [31] Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 1999; 399: A23-31.
32. [32] Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron 2001; 32: 177-80.
33. [33] Bartolini M, Bertucci C, Cavrini V, et al. Beta-Amyloidaggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol 2003; 65: 407-16.
34. [34] Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke: a placebo controlled, double-blind clinical trial. Stroke 1998; 29: 12-17.
35. [35] Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30: 47-55.
36. [36] Porciuncula LO, Rocha JB, Boeck CR, et al. Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons. Neurosci. Lett 2001; 299: 217-20.
37. [37] Satoh T, Ishige K, Sagara Y. Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps. Neurosci. Lett 2004; 371: 1-5.
38. [38] Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun 2013; 4: 1332.
39. [39] Xie L, Zheng W, Xin N, et al. Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake. Neurochem Int 2012; 61: 334-40.
40. [40] Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69: 2205-12.
41. [41] Van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009; 72: 1056-61.
42. [42] Frantz S. Drug discovery: playing dirty. Nature 2005; 437: 942-3.
43. [43] Goedert M, Spillantini MG.A century of Alzheimer's disease. Science 2006; 314: 777-81.
44. [44] Kim HG, Oh MS. Herbal Medicines for the Prevention and Treatment of Alzheimer’s Disease. Curr Pharm Des 2012; 18: 5775.
45. [45] Marangoni AG. Enzyme kinetics: a modern approach. Wiley- Interscience 2003; Chapter 8.
46. [46] Castro A, Martinez A. Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Curr Pharm Des 2006; 12: 4377-87.
47. [47] Recanatini M, Valenti P. Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimer’s Disease Therapeutics. Curr Pharm Des 2004; 10: 3157-66.
48. [48] Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011; 10: 307-17.